The present invention provides compositions and methods for the inhibition of MASP-1 and / or MASP-2 and / or MASP-3. The present invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from, or at risk of developing, a
disease or condition selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related
macular degeneration,
arthritis,
macular degeneration,
macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular degeneration, macular The present invention relates to an inhibitor of MASP-3-dependent complement activation in an amount effective to inhibit MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation, for example, MASP-3-dependent complement activation. In some embodiments, a MASP-2 inhibitor and a MASP-1 inhibitor, a MASP-2 inhibitor and a MASP-3 inhibitor, a MASP-3 inhibitor and a MASP-1 inhibitor, or a MASP-1 inhibitor, a MASP-2 inhibitor and a MASP-3 inhibitor are administered to the subject.